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cost-effective strategy. During recent meetings of the Pal-
estinian Society of Gastroenterology and the Mediterranean 
Task force for Cancer Control (MTCC) in Jericho, and the 
Patient’s Friends Society of Jerusalem in Hebron the issue 
of hereditary CRC in the Middle East was discussed and 
the idea was conceived to establish a network on hereditary 
colorectal cancer (HCCN-ME) with the goal of improving 
care for high-risk groups in the Middle East and (Eastern) 
Mediterranean Countries.
Keywords Lynch syndrome · Familial colorectal cancer · 
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Abstract Colorectal cancer (CRC) has a very high inci-
dence in the western world. Data from registries in the 
Middle East showed that the incidence of CRC is rela-
tively low in these countries. However, these data also 
showed that CRC incidence has increased substantially 
over the past three decades and that a high proportion of 
cases are diagnosed at an early age (<50 years). In view of 
these findings, more attention should be paid to prevention. 
Because of the often limited financial resources, focused 
screening of individuals with hereditary CRC, in particu-
lar those with Lynch syndrome, appears to be the most 
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Introduction
In the western world, colorectal cancer (CRC) has a very high 
incidence, occupying the second or third position on the list 
of commonest cancers in most countries (http://Globocan.
iarc.fr). Detailed information on the epidemiology of CRC 
in the Middle East is limited to the few cancer registries cur-
rently in existence. Data from the Gharbia registry (Egyptian 
region with 4 million inhabitants) showed that the incidence 
of CRC is relatively low (5/100,000), with higher rates in 
urban areas compared to rural areas [1]. Data from the Israel 
National Cancer Registry confirms the low incidence of CRC 
in the Arab population (Israel National Cancer Registry web-
site). However, data from this registry also showed that CRC 
incidence has increased substantially over the past three dec-
ades, with the age standardized rate (ASR) increasing from 
5.5/100,000 in the 1980s to around 20/100,000 in 2013.
An interesting characteristic of the epidemiology of 
CRC in the Middle East is the high proportion of cases 
that are diagnosed at an early age. For example, 24% of 
the CRC cases in the Gharbia district in Egypt and 25% 
of CRC cases in Iran were diagnosed before ages 40 and 
45, respectively [1, 2]. These observations may be partly 
explained by the different age structure of the population, 
with a higher proportion of the population age <50 in the 
Middle East compared to the Western countries.
In view of the increasing incidence of CRC and the early 
onset of CRC in Middle East countries, greater attention 
should be paid to the prevention of CRC in this region.
Prevention of CRC
In general, two options for prevention of CRC are avail-
able: (1) offering screening to the general population using 
fecal occult blood testing (FOBT), or (2) focusing screen-
ing on high risk groups. The first option has already been 
implemented in many Western countries. Experience with 
a nationwide FOBT screening program (age: 55–75) that 
started in the Netherlands in 2014 is very promising. The 
participation rate is very high (>70% out of 4 million peo-
ple) and the yield of colonoscopies is substantial, with 8% 
CRC and >40% advanced adenomas (http://www.rivm.
nl). However, a large-scale population-based program is 
relatively expensive (>80  million Euro’s per year in the 
Netherlands). In view of the lower incidence of CRC in 
the Middle East and limited financial resources, focusing 
screening on high-risk groups might be more cost-effective.
What proportion of CRC in the Middle East 
is familial or hereditary?
Studies in Western countries have shown that 10–15% of 
all CRCs are caused by hereditary factors (Fig. 1). About 
10% is caused by clustering of CRC in families with-
out an identified high penetrance gene defect, a group 
referred to as familial colorectal cancer. Approximately 
2% is associated with polyposis syndromes, mainly 
the syndromes caused by mutation(s) in the APC gene 
(familial adenomatous polyposis) and MUTYH (MUTYH-
associated polyposis) [3].
The most common hereditary CRC syndrome is Lynch 
syndrome, which is responsible for 3–5% of all CRC 
cases. This autosomal dominant syndrome is caused by 
mutations in one of the mismatch repair (MMR) genes 
(MLH1, MSH2 (EPCAM), MSH6 and PMS2). The main 
features of the syndrome are (1) an early age of onset of 
CRC, (2) a high risk of developing multiple tumors, and 
(3) an association with the development of other cancers 
(endometrium, ovaries, urinary tract, stomach and other 
sites). The hallmark of the syndrome is the presence of 
microsatellite instability (MSI) in the tumor. Several stud-
ies from the Middle East reported Lynch syndrome fami-
lies, and the clinical features of Lynch syndrome families 
appear to be similar to those seen in Western families [4].
A study from Egypt, focused on obtaining a detailed fam-
ily history in a series of consecutive patients with CRC, sug-
gested that 7–14% of cases show evidence for familial or 
hereditary CRC [5]. Other studies evaluated the presence of 
MMR deficiency in various countries in the Middle East with 
CRC and found evidence for MMR deficiency in approxi-
mately 11–20% of tumors [6–8]. These data thus suggest that 
the proportion of familial or hereditary CRC in the Middle 
East is probably comparable to that in Western countries.
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Fig. 1  Etiology of colorectal cancer (CRC)
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How can Lynch syndrome families be identified 
in the Middle East?
Obtaining a detailed family history is the most cost-effec-
tive approach to identifying familial and hereditary CRC. 
If facilities for tumor analysis [MSI or immunohistochemi-
cal analysis of the MMR-proteins (IHC)] are limited, the 
classic clinical criteria (revised Amsterdam criteria: 3 
CRCs or associated cancers in two successive generations, 
one cancer diagnosed before age 50 years) [9] can be used 
to assess whether one is dealing with a Lynch syndrome 
family. However, families that comply with only some of 
these criteria should not be excluded from colonoscopic 
surveillance.
Currently, the best way to identify Lynch syndrome fam-
ilies is by applying MSI analysis or immunohistochemical 
analysis (IHC) of tumor MMR protein expression. This 
analysis of CRC tumors can be performed in suspected 
families based on the main features of Lynch syndrome: 
early age of onset (<50 years), the occurrence of multiple 
tumors or clustering of CRC in the family. A relatively 
new approach is systematic screening by MSI or IHC of 
all newly diagnosed CRC <70 years, a method that is now 
being implemented in many Western countries. In addition, 
an increasing numbers of studies are reporting the testing 
of multiple cancer-associated genes by next generation 
sequencing (NGS) [10, 11].
The importance of recognizing CMMRD 
in the Middle East
A distinct means to identify Lynch syndrome families in 
the Middle East is through recognition of constitutional 
mismatch repair deficiency (CMMRD) [12, 13]. This is a 
very rare autosomal recessive syndrome characterized by 
the development of multiple tumors in the first and second 
decade of life. These malignancies include brain tumors, 
cancer of the colon and small bowel, and hematological 
malignancies such as leukemia and non-Hodgkin lym-
phoma. Other features include the development of multi-
ple colorectal adenomas in the second decade of life and 
the presence of café au lait spots. CMMRD is caused by 
two germline mutations in the same MMR gene. Marriage 
between cousins, especially in rural areas, is relatively 
common in the Middle East and this custom is therefore 
also likely in families with Lynch syndrome. Parents who 
are both affected with or predisposed to Lynch syndrome 
have a 25% risk of having a child who develops CMMRD.
Lynch syndrome should therefore be considered when a 
child has features of CMMRD (Table 1). However, as the 
syndrome is typically caused by mutations in PMS2, a gene 
associated with a relatively low CRC penetrance, CRC 
might even be absent in family members of a CMMRD 
patient. CMMRD diagnosis can be made by immunohisto-
chemical analysis of the MMR proteins in both normal and 
tumor tissue, and by germline mutation analysis.
Middle East network for hereditary CRC
In conclusion, in view of the increasing incidence of CRC 
in the Middle East and the substantial number of early 
onset CRC cases, more attention should be paid to preven-
tion. In light of often limited financial resources, focused 
screening of individuals with hereditary CRC, in particular 
those with Lynch syndrome, appears to be the most cost-
effective strategy.
During recent meetings of the Palestinian Society of 
Gastroenterology and the Mediterranean Task force for 
Cancer Control (MTCC) in Jericho, and the Patient’s 
Friends Society of Jerusalem in Hebron on April 7 and 8, 
2017, the issue of hereditary CRC in the Middle East was 
discussed and the idea was conceived to establish a Middle 
East Network on Hereditary Colorectal Cancer  (HCCN-
ME). The main goal of this new Network is to improve care 
for these high-risk groups in the Middle East and Eastern 
Mediterranean Countries. Our activities will include (1) 
an inventory of current care in the countries concerned, 
(2) development of guidelines for diagnosis and manage-
ment, (3) development of patient information pamphlets, 
(4) identification of referral centers for genetic counseling, 
Table 1  Features of constitutional mismatch repair deficiency 
(CMMRD) [13]
Feature Age range 
at diagnosis 
(median)
Hematological malignancies
Non-hodgkin lymphoma 0.4–17 (5 years)
Lymphoid leukemia 2–21 (6 years)
Acute myeloid leukemia 6–17 (9.5 years)
Malignant brain and central nervous system tumors
High-grade gliomas 2–40 (9.5 years)
sPNET 4–17 (8 years)
Medulloblastoma 4–12 (7 years)
LS-associated carcinomas
Colon/rectum 8–48 (16 years)
Duodenum/jejunum/ileum 11–42 (28 years)
Endometrium 23–44 (28 years)
Bladder/ureter/renal pelvis/ovaries unknown
Benign features
Adenomas/polyps of colon, rectum and duodenum 6–46 (14 years)
Café au Lait
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MSI analysis and DNA analysis in the various countries/
regions, (5) establishing registries to guarantee lifetime 
surveillance, and (6) development of a website. Individu-
als and organizations in Middle East countries and other 
(Eastern) Mediterranean countries interested in participat-
ing in this network are invited to contact the Secretariat of 
the network: Dutch Hereditary Colorectal Cancer Registry; 
Leiden, The Netherlands; hfavasen@stoet.nl.  Information 
on the network can be found at: http://www.hccn-me.com.
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